Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hoff

Showing results (411-420 of 514) with videos related to

Pageof 52
Sort By:
Calcified Tissue International|October 21, 2025
Birth Characteristics and Bone Mineral Density and Content in Young Adults: The HUNT Study, NorwayH T Holltrø, T I L Nilsen, B Schei, et al.
Investigational New Drugs|June 6, 2008
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman, Gauri Varadhachary, Scott Kopetz, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 18, 2026
Are birth characteristics related to bone quality measures in young adults? The HUNT study, NorwayH T Holltrø, T I L Nilsen, B Schei, et al.
Clinics (Sao Paulo, Brazil)|October 13, 2021
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapyLaura Testa, Max Mano, Roberto Jun Arai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2bJames C Yao, Alexandria Phan, Paulo M Hoff, et al.
Oncotarget|October 7, 2015
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practiceLuís Felipe Campesato, Romualdo Barroso-Sousa, Leandro Jimenez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injuryMichael J Overman, Dipen M Maru, Chusilp Charnsangavej, et al.
BMC Cancer|January 12, 2018
CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extensionRicardo Celestino, Torfinn Nome, Ana Pestana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJean-Yves Douillard, Paulo M Hoff, Jamey R Skillings, et al.
Clinical Colorectal Cancer|January 27, 2016
High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 PatientsBruno Conte, Ben George, Michael Overman, et al.
Pageof 52

Showing results (411-420 of 514) with videos related to

Sort By:
Pageof 52
Calcified Tissue International|October 21, 2025
Birth Characteristics and Bone Mineral Density and Content in Young Adults: The HUNT Study, NorwayH T Holltrø, T I L Nilsen, B Schei, et al.
Investigational New Drugs|June 6, 2008
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman, Gauri Varadhachary, Scott Kopetz, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 18, 2026
Are birth characteristics related to bone quality measures in young adults? The HUNT study, NorwayH T Holltrø, T I L Nilsen, B Schei, et al.
Clinics (Sao Paulo, Brazil)|October 13, 2021
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapyLaura Testa, Max Mano, Roberto Jun Arai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2bJames C Yao, Alexandria Phan, Paulo M Hoff, et al.
Oncotarget|October 7, 2015
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practiceLuís Felipe Campesato, Romualdo Barroso-Sousa, Leandro Jimenez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injuryMichael J Overman, Dipen M Maru, Chusilp Charnsangavej, et al.
BMC Cancer|January 12, 2018
CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extensionRicardo Celestino, Torfinn Nome, Ana Pestana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJean-Yves Douillard, Paulo M Hoff, Jamey R Skillings, et al.
Clinical Colorectal Cancer|January 27, 2016
High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 PatientsBruno Conte, Ben George, Michael Overman, et al.
Pageof 52